This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Progress and Promise

Paul A. Bleicher, MD, PhD; Steven P. Balk, MD, PhD

Arch Dermatol. 1988;124(3):359-363.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

T-cell has been applied clinically as a technique to demonstrate clonality of T lymphocytes.^1-3 Although often difficult to demonstrate, clonality is considered to be a sine qua non of malignancy. The occurrence of a unique chromosomal translocation (eg, the translocation of the long arm of chromosome 22, the Philadelphia¹ chromosome) in chronic myelogenous leukemia is strong evidence for the clonal derivation of this malignancy. It is understood that the malignant transformation of the leukemic cells must occur at the time of, or after, the Philadelphia¹ translocation so that each malignant cell contains the translocated chromosome. The immunohistochemical demonstration that almost every cell in a proliferation of B lymphocytes expresses one immunoglobulin light chain (either or X) is evidence that the cells are likely to all be members of a single clone that may be malignant. Again, the malignant transformation of the B lymphocyte must occur at . . . [Full Text PDF of this Article]

Author Affiliations
Department of Dermatology Harvard Medical School Boston, MA 02115; Division of Hematology and Oncology Department of Medicine Beth Israel Hospital Boston, MA 02115

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?